The Microbes as Therapeutics GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field.
This conference will delve into the rapidly advancing field of microbial therapies—genetically modified microorganisms with reduced or eliminated pathogenicity, and engineered to enhance therapeutic efficacy. As our understanding of microbial interactions with the human body deepens, new opportunities are emerging to harness these interactions for therapeutic benefit. Advances in genetic engineering now enable precise manipulation of bacteria, unlocking novel ways to modulate the immune system and metabolism with the potential for long-lasting therapeutic effects. In addition to efficacy, the conference will address the critical challenge of managing side effects, as overcoming these will be key to the widespread adoption of microbial therapies.
A key focus of the conference will be the use of microbes in cancer therapeutics. Microbial therapies provide solutions to challenges that current treatments struggle to overcome, such as refractory metastatic cancers, multidrug resistance, and immune evasion. Engineered microbes have demonstrated promise across a variety of cancer types, including solid tumors (digestive and reproductive systems), melanoma, sarcoma, and hematologic cancers. Beyond oncology, microbial therapies hold immense potential for treating a broad range of conditions—from metabolic disorders and autoimmune diseases to hospital-acquired infections, inflammatory bowel disease, wound healing and arthritis. In these contexts, microbes are being engineered to thrive in harsh environments, alter local microbiomes, and produce immune-regulating molecules. The potential to treat, or even manage chronically, previously refractory diseases is driving significant innovation. With rapid advances in genetic manipulation dramatically shortening the path from concept to clinical trials, microbial therapies are poised to become a cornerstone of modern medicine. If you’re engaged in engineering microbial therapeutics as a new pillar of healthcare, this conference is for you.
